Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Etoposide Capsule Clear all
Recruiting Phase 1Phase 2 Interventional

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

NCT06937866
View directory record Official record
Conditions
Germ Cell Tumor
Interventions
Zanzalintinib, Etoposide Capsule
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 11, 2026, 2:08 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

NCT01064466
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ETOPOSIDE - Usual, ETOPOSIDE - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 11, 2026, 2:08 PM EDT
Active, not recruiting Phase 2 Interventional

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

NCT03116971
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
M3814, Cisplatin, Etoposide
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Mesa, Arizona • Santa Rosa, California • Whittier, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

NCT04154189
View directory record Official record
Conditions
Osteosarcoma
Interventions
Lenvatinib, Ifosfamide, Etoposide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 11, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated)
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

NCT00927875
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
BMS-833923, Carboplatin, Etoposide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01197560
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab, Etoposide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Burbank, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

NCT02289690
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Veliparib, Carboplatin, Etoposide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gefitinib plus etoposide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT02128230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
Device · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

NCT04924101
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab, MK-4830, Boserolimab, Lenvatinib, Etoposide, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Gilbert, Arizona • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Results available

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

NCT01059071
View directory record Official record
Conditions
Neuroblastoma
Interventions
DFMO, Etoposide
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 11, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

NCT00572169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, Dexamethasone, Adriamycin, Cisplatin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

NCT00613223
View directory record Official record
Conditions
Gliosarcoma, Glioblastoma
Interventions
Vandetanib and Etoposide
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT00481832
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

NCT04189952
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
Interventions
Acalabrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 11, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

NCT01084759
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone injection, Etoposide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 11, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

NCT05815160
View directory record Official record
Conditions
Small Cell Lung Cancer Recurrent
Interventions
Debio 0123, Etoposide, Carboplatin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 11, 2026, 2:08 PM EDT